somatostatin

Somatostatin 1-28 acetate circulates in human plasma. Approximately 46% of the total somatostatin-like immunoreactivity in plasma is due to Somatostatin 1-28 acetate.

Somatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues that regulates the endocrine system. It is secreted by the D cells of the islets to inhibit the release of insulin and

Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.

Somatostatin acetate is an endogenously secreted inhibitor of cell proliferation with potential antitumor activity for the study of cancer and neurological disorders.

Tyr-Somatostatin-14 acetate is a customized peptide that adds a Tyrosine amino acid to Somatostatin-14.

[Tyr1]-Somatostatin-14 may bind to SSTR2.

Somatostatin is an endogenous neuropeptide hormone found in the brain and pancreas. Somatostatin binds several isoforms of the somatostatin receptor, exhibiting anxiolytic, antiepileptic/anticonvulsant, and anorexigenic activities.

Cyclic somatostatin Acetate(38916-34-6(free base)) (Somatostatin-14) is a cyclic tetradecapeptide regulating many endocrine and nervous system functions.

'(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analogue exhibiting varying affinity for somatostatin receptors, with dissociation constants (Kd) of 0.61 nM for SSTR5, 11.05 nM for SSTR3, 23.5 nM for SSTR2, 1200 nM for SSTR1, and >1000 nM for SSTR4, respectively [1].'

Somatostatin receptor agonist, derived from the post-translational cleavage of prosomatostatin.

[Tyr12] Somatostatin 28 (1-14) is an analogue of the N-terminal fragment of the neuropeptide Somatostatin-28, encompassing the first 14 amino acids of the sequence.

Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a somatostatin agonist used in cancer research [1].

[Nle8] Somatostatin (1-28), a derivative of somatostatin (1-28) with norleucine (Nle) substituting for methionine at position 8, enhances amylase release and elevates cyclic AMP levels in pancreatic acini [1].

[D-Trp8,Tyr11] Somatostatin, an analogue of the hormone somatostatin that modulates numerous bodily functions, is characterized by the substitution of DTrp8, which can enhance its stability [1].

[Tyr11]-Somatostatin is a neuroactive peptide utilized in proteomics research. It belongs to a class of neuroactive substances that play a role in modulating retinal physiology.

Somatostatin-28 (1-12) is a fragment of somatostatin that is monitored in brain tissue to track the processing of somatostatin.

Tyr-Somatostatin-14 is a modified peptide incorporating an additional Tyrosine (amino acid) into the structure of Somatostatin-14.

Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28, which originates from the posttranslational cleavage of prosomatostatin, derived from the larger precursor preprosomatostatin.

Cyclic somatostatin (SRIF-14) is a cyclic tetradecapeptide that regulates various endocrine and nervous system functions.

(D-Trp8,D-Cys14)-Somatostatin-14, a synthetic analogue of somatostatin, is used in the research of metabolic-related diseases [1] [2].

[D-Trp8] Somatostatin-14 is a potent tetradecapeptide analog of native somatostatin, exhibiting increased efficacy [1].

Tyr-Somatostatin-28 is a somatostatin derivative comprising Somatostatin-28 with an additional Tyrosine amino acid [1].

Cyclosomatostatin Acetate is an effective antagonist of the somatostatin receptor.Cyclosomatostatin Acetate inhibits SSTR1 signaling and decreases cell proliferation, ALDH+ cell population size, and sphere-formation in colorectal cancer cells.

Cyclosomatostatin TFA, a potent somatostatin (SST) receptor antagonist, inhibits type 1 somatostatin receptor (SSTR1) signaling, reducing cell proliferation, the size of the ALDH+ cell population, and sphere-formation in colorectal cancer (CRC) cells [1].